Sensitization of cerebral tissue in nude mice with photodynamic therapy induces ADAM17/TACE and promotes glioma cell invasion

Cancer Letters

Volumn 265, Issue 2, 2008, Pages 177-187

  Zheng, Xuguang ^a   Jiang, Feng ^a   Katakowski, Mark ^a   Zhang, Xuepeng ^a,b   Jiang, Hao ^a   Zhang, Zheng Gang ^a   Chopp, Michael ^a,c  

^a HENRY FORD HOSPITAL   (United States)

^b North China Coal Medical University   (China)

^c OAKLAND UNIVERSITY   (United States)

Author keywords

ADAM17; Akt; EGFR; Glioma; Invasion; Photodynamic therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOTOFRIN; PHOTOSENSITIZING AGENT; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN TISSUE; CANCER GRAFT; CELL INVASION; CONTROLLED STUDY; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; LASER; LIGHT EXPOSURE; MOUSE; NONHUMAN; NUDE MOUSE; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING;

ADAM PROTEINS; ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; ENZYME INDUCTION; GLIOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHOTOCHEMOTHERAPY;

MUS MUSCULUS;

EID: 43949092082     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.02.023     Document Type: Article

References (50)

1. Henderson B.W., and Dougherty T.J. How does photodynamic therapy work?. Photochem. Photobiol. 55 (1992) 145-157
2. Chopp M., Dereski M.O., Madigan L., Jiang F., and Logie B. Sensitivity of 9L gliosarcomas to photodynamic therapy. Radiat. Res. 146 (1996) 461-465
3. Muller P., and Wilson B. Photodynamic therapy of brain tumours - post-operative "field fractionation". J. Photochem. Photobiol. B 9 (1991) 117-119
4. Jiang F., Lilge L., Belcuig M., Singh G., Grenier J., Li Y., and Chopp M. Photodynamic therapy using Photofrin in combination with buthionine sulfoximine (BSO) to treat 9L gliosarcoma in rat brain. Lasers Surg. Med. 23 (1998) 161-166
5. Fingar V.H., Kik P.K., Haydon P.S., Cerrito P.B., Tseng M., Abang E., and Wieman T.J. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br. J. Cancer 79 (1999) 1702-1708
6. van Geel I.P., Oppelaar H., Rijken P.F., Bernsen H.J., Hagemeier N.E., van der Kogel A.J., Hodgkiss R.J., and Stewart F.A. Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy. Br. J. Cancer 73 (1996) 288-293
7. Engbrecht B.W., Menon C., Kachur A.V., Hahn S.M., and Fraker D.L. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Res. 59 (1999) 4334-4342
8. Mitra S., Cassar S.E., Niles D.J., Puskas J.A., Frelinger J.G., and Foster T.H. Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha. Mol. Cancer Ther. 5 (2006) 3268-3274
9. Foster T.H., Murant R.S., Bryant R.G., Knox R.S., Gibson S.L., and Hilf R. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat. Res. 126 (1991) 296-303
10. Busch T.M., Hahn S.M., Evans S.M., and Koch C.J. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide]. Cancer Res. 60 (2000) 2636-2642
11. Zheng X., Jiang F., Katakowski M., Kalkanis S.N., Hong X., Zhang X., Zhang Z.G., Yang H., and Chopp M. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci. 98 (2007) 674-684
12. Zhang X., Jiang F., Kalkanis S.N., Yang H., Zhang Z., Katakowski M., Hong X., Zheng X., and Chopp M. Combination of surgical resection and photodynamic therapy of 9L gliosarcoma in the nude rat. Photochem. Photobiol. 82 (2006) 1704-1711
13. deCarvalho A.C., Zhang X., Roberts C., Jiang F., Kalkanis S.N., Hong X., Lu M., and Chopp M. Subclinical photodynamic therapy treatment modifies the brain microenvironment and promotes glioma growth. Glia 55 (2007) 1053-1060
14. Tsatas D., Kanagasundaram V., Kaye A., and Novak U. EGF receptor modifies cellular responses to hyaluronan in glioblastoma cell lines. J. Clin. Neurosci. 9 (2002) 282-288
15. Van Meter T.E., Broaddus W.C., Rooprai H.K., Pilkington G.J., and Fillmore H.L. Induction of membrane-type-1 matrix metalloproteinase by epidermal growth factor-mediated signaling in gliomas. Neuro. Oncol. 6 (2004) 188-199
16. Laerum O.D., Nygaar S.J., Steine S., Mork S.J., Engebraaten O., Peraud A., Kleihues P., and Ohgaki H. Invasiveness in vitro and biological markers in human primary glioblastomas. J. Neurooncol. 54 (2001) 1-8
17. Wells A. EGF receptor. Int. J. Biochem. Cell. Biol. 31 (1999) 637-643
18. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 13 (1999) 2905-2927
19. Lal A., Glazer C.A., Martinson H.M., Friedman H.S., Archer G.E., Sampson J.H., and Riggins G.J. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 62 (2002) 3335-3339
20. Canning M.T., Postovit L.M., Clarke S.H., and Graham C.H. Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Exp. Cell. Res. 267 (2001) 88-94
21. Korbelik M. PDT-associated host response and its role in the therapy outcome. Lasers Surg. Med. 38 (2006) 500-508
22. Gomer C.J., Ferrario A., Luna M., Rucker N., and Wong S. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg. Med. 38 (2006) 516-521
23. Ferrario A., Chantrain C.F., von Tiehl K., Buckley S., Rucker N., Shalinsky D.R., Shimada H., DeClerck Y.A., and Gomer C.J. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res. 64 (2004) 2328-2332
24. Subarsky P., and Hill R.P. The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 20 (2003) 237-250
25. Munoz-Najar U.M., Neurath K.M., Vumbaca F., and Claffey K.P. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 25 (2006) 2379-2392
26. Yoon S.O., Shin S., and Mercurio A.M. Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin. Cancer Res. 65 (2005) 2761-2769
27. Stoeltzing O., McCarty M.F., Wey J.S., Fan F., Liu W., Belcheva A., Bucana C.D., Semenza G.L., and Ellis L.M. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J. Natl. Cancer Inst. 96 (2004) 946-956
28. Graham C.H., Forsdike J., Fitzgerald C.J., and Macdonald-Goodfellow S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int. J. Cancer 80 (1999) 617-623
29. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., and Semenza G.L. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88 (2000) 2606-2618
30. Buchler P., Reber H.A., Lavey R.S., Tomlinson J., Buchler M.W., Friess H., and Hines O.J. Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J. Surg. Res. 120 (2004) 295-303
31. Kaur B., Khwaja F.W., Severson E.A., Matheny S.L., Brat D.J., and Van Meir E.G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro. Oncol. 7 (2005) 134-153
32. Black R.A. Tumor necrosis factor-alpha converting enzyme. Int. J. Biochem. Cell. Biol. 34 (2002) 1-5
33. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., and Cerretti D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 (1997) 729-733
34. Buxbaum J.D., Liu K.N., Luo Y., Slack J.L., Stocking K.L., Peschon J.J., Johnson R.S., Castner B.J., Cerretti D.P., and Black R.A. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273 (1998) 27765-27767
35. Zatovicova M., Sedlakova O., Svastova E., Ohradanova A., Ciampor F., Arribas J., Pastorek J., and Pastorekova S. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br. J. Cancer 93 (2005) 1267-1276
36. Crowe P.D., Walter B.N., Mohler K.M., Otten-Evans C., Black R.A., and Ware C.F. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J. Exp. Med. 181 (1995) 1205-1210
37. Mullberg J., Durie F.H., Otten-Evans C., Alderson M.R., Rose-John S., Cosman D., Black R.A., and Mohler K.M. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J. Immunol. 155 (1995) 5198-5205
38. Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter H.L., Chen W.J., Clay W.C., Didsbury J.R., Hassler D., Hoffman C.R., Kost T.A., Lambert M.H., Leesnitzer M.A., McCauley P., McGeehan G., Mitchell J., Moyer M., Pahel G., Rocque W., Overton L.K., Schoenen F., Seaton T., Su J.L., Becherer J.D., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385 (1997) 733-736
39. Bennett T.A., Lynam E.B., Sklar L.A., and Rogelj S. Hydroxamate-based metalloprotease inhibitor blocks shedding of l-selectin adhesion molecule from leukocytes: functional consequences for neutrophil aggregation. J. Immunol. 156 (1996) 3093-3097
40. Hooper N.M., Karran E.H., and Turner A.J. Membrane protein secretases. Biochem. J. 321 Pt 2 (1997) 265-279
41. Fan H., and Derynck R. Ectodomain shedding of TGF-alpha and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascades. EMBO J. 18 (1999) 6962-6972
42. Fan H., Turck C.W., and Derynck R. Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide. J. Biol. Chem. 278 (2003) 18617-18627
43. Bauvois B. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis?. Oncogene 23 (2004) 317-329
44. Ramnarain D.B., Park S., Lee D.Y., Hatanpaa K.J., Scoggin S.O., Otu H., Libermann T.A., Raisanen J.M., Ashfaq R., Wong E.T., Wu J., Elliott R., and Habib A.A. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res. 66 (2006) 867-874
45. Lee D.C., Sunnarborg S.W., Hinkle C.L., Myers T.J., Stevenson M.Y., Russell W.E., Castner B.J., Gerhart M.J., Paxton R.J., Black R.A., Chang A., and Jackson L.F. TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann. NY Acad. Sci. 995 (2003) 22-38
46. Hart S., Fischer O.M., and Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 64 (2004) 1943-1950
47. Ruhe J.E., Streit S., Hart S., and Ullrich A. EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing. Cell Signal 18 (2006) 1515-1527
48. Andersson U., Guo D., Malmer B., Bergenheim A.T., Brannstrom T., Hedman H., and Henriksson R. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol. (Berl) 108 (2004) 135-142
49. Mikkelsen T. Cytostatic agents in the management of malignant gliomas. Cancer Control 5 (1998) 150-162
50. Brown J.M. Tumor hypoxia in cancer therapy. Methods Enzymol. 435 (2007) 297-321